Dermapharm Holding SE (FRA:DMP)
Germany · Delayed Price · Currency is EUR 35.05
+0.05 (0.14%)
At close: Jan 30, 2026
Dermapharm Holding SE Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,173 | 1,195 | 1,150 | 1,040 | 959.6 | 807.64 |
Other Revenue | 0.75 | 0.75 | 0.42 | 0.25 | 0.49 | 0.67 |
| 1,174 | 1,195 | 1,151 | 1,041 | 960.09 | 808.31 | |
Revenue Growth (YoY) | 0.02% | 3.89% | 10.59% | 8.38% | 18.78% | 13.15% |
Cost of Revenue | 419.03 | 445.6 | 446.6 | 391.85 | 349.87 | 354.42 |
Gross Profit | 755.11 | 749.85 | 704.14 | 648.7 | 610.22 | 453.89 |
Selling, General & Admin | 297.14 | 287.43 | 271.01 | 190.56 | 168.95 | 158.06 |
Other Operating Expenses | 148.99 | 158.18 | 151.21 | 117.72 | 99.68 | 110.13 |
Operating Expenses | 525.35 | 527.78 | 510.99 | 365.98 | 314.31 | 313.77 |
Operating Income | 229.76 | 222.07 | 193.16 | 282.72 | 295.91 | 140.12 |
Interest Expense | -52.27 | -58.41 | -54.97 | -12.34 | -8.84 | -9.36 |
Interest & Investment Income | 8.09 | 13.99 | 2.49 | 0.33 | 4.02 | 0.51 |
Earnings From Equity Investments | 1.13 | 1.52 | -7.16 | -13.54 | 0.32 | -1.5 |
Currency Exchange Gain (Loss) | 1.4 | 1.4 | -1.95 | 0.37 | 2.28 | -1.63 |
Other Non Operating Income (Expenses) | -8.6 | -0.96 | -16.63 | -1.12 | -0.83 | 0.24 |
EBT Excluding Unusual Items | 179.51 | 179.61 | 114.93 | 256.43 | 292.86 | 128.38 |
Merger & Restructuring Charges | - | - | - | - | -0.6 | - |
Impairment of Goodwill | -2.12 | -2.12 | - | -36.45 | -5.43 | - |
Gain (Loss) on Sale of Investments | -0 | -0 | -1.98 | - | 9.06 | - |
Gain (Loss) on Sale of Assets | 0.63 | 0.63 | 2.96 | 3.13 | 1.38 | 0.23 |
Asset Writedown | -6.21 | -6.21 | -15.82 | -7.03 | -4.48 | -3.58 |
Other Unusual Items | - | - | 5.78 | - | - | - |
Pretax Income | 171.9 | 172.01 | 106 | 216.3 | 292.98 | 125.28 |
Income Tax Expense | 57.66 | 60.27 | 45.46 | 83.68 | 84.07 | 39.36 |
Earnings From Continuing Operations | 114.25 | 111.74 | 60.53 | 132.62 | 208.9 | 85.93 |
Minority Interest in Earnings | 1.78 | 2.05 | 1.83 | 1.62 | 0.68 | -0.1 |
Net Income | 116.03 | 113.79 | 62.37 | 134.24 | 209.58 | 85.83 |
Net Income to Common | 116.03 | 113.79 | 62.37 | 134.24 | 209.58 | 85.83 |
Net Income Growth | 28.09% | 82.45% | -53.54% | -35.95% | 144.19% | 11.18% |
Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Outstanding (Diluted) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Change (YoY) | -0.14% | - | - | - | - | - |
EPS (Basic) | 2.15 | 2.11 | 1.16 | 2.49 | 3.89 | 1.59 |
EPS (Diluted) | 2.15 | 2.11 | 1.16 | 2.49 | 3.89 | 1.59 |
EPS Growth | 28.27% | 82.45% | -53.54% | -35.91% | 144.65% | 11.19% |
Free Cash Flow | 164.39 | 163.14 | 177.88 | 249.52 | 189.17 | 90.3 |
Free Cash Flow Per Share | 3.05 | 3.03 | 3.30 | 4.63 | 3.51 | 1.68 |
Dividend Per Share | 0.900 | 0.900 | 0.880 | 1.050 | 2.170 | 0.880 |
Dividend Growth | 2.27% | 2.27% | -16.19% | -51.61% | 146.59% | 10.00% |
Gross Margin | 64.31% | 62.72% | 61.19% | 62.34% | 63.56% | 56.15% |
Operating Margin | 19.57% | 18.58% | 16.79% | 27.17% | 30.82% | 17.34% |
Profit Margin | 9.88% | 9.52% | 5.42% | 12.90% | 21.83% | 10.62% |
Free Cash Flow Margin | 14.00% | 13.65% | 15.46% | 23.98% | 19.70% | 11.17% |
EBITDA | 257.07 | 250.77 | 220.31 | 302.36 | 312.36 | 155.05 |
EBITDA Margin | 21.89% | 20.98% | 19.14% | 29.06% | 32.53% | 19.18% |
D&A For EBITDA | 27.32 | 28.7 | 27.15 | 19.64 | 16.45 | 14.92 |
EBIT | 229.76 | 222.07 | 193.16 | 282.72 | 295.91 | 140.12 |
EBIT Margin | 19.57% | 18.58% | 16.79% | 27.17% | 30.82% | 17.34% |
Effective Tax Rate | 33.54% | 35.04% | 42.89% | 38.69% | 28.70% | 31.41% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.